• 1
    Lightner VA, Marks JR, McCachren SM. Epithelial cells are an important source of tenascin in normal and malignant human breast tissue. Exp Cell Res 1994;210: 17784.
  • 2
    Yoshida T, Matsumoto E, Hanamura N, Kalembeyi I, Katsuta K, Ishihara A, Sakakura T. Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast. J Pathol 1997;182: 4218.
  • 3
    Hanamura N, Yoshida T, Matsumoto E, Kawarada Y, Sakakura T. Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. Int J Cancer 1997;73: 105.
  • 4
    Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000;218: 23559.
  • 5
    Ishihara A, Yoshida T, Tamaki, Sakakura T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res 1995;1: 103541.
  • 6
    Jahkola T, Toivonen T, Nordling S, von Smitten K, Virtanen I. Expression of tenascin-C in intraductal carcinoma of human breast: relationship to invasion. Eur J Cancer 1998;34: 168792.
  • 7
    Kressner U, Lindmark G, Tomasini-Johansson B, Bergstrom R, Gerdin B, Pahlman L, Glimelius B. Stromal tenascin distribution as a prognostic marker in colorectal cancer. Br J Cancer 1997;76: 52630.
  • 8
    Jahkola T, Toivonen T, von Smitten K, Nordling S, von Boguslawki K, Haglund C, Nevanlinna H. Tenascin-C expression in the invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer 1998;78: 150713.
  • 9
    Yoshida T, Yoshimura E, Numata H, Sakakura Y, Sakakura T. Involvement of tenscin-c in migration and proliferation of laryngeal cancer cells. Virchows Arch 1999;435: 496500.
  • 10
    Orend G, Chiquet-Ehrismann R. Adhesion modulation by antiadhesive molecules of the extracellular matrix. Exp Cell Res 2000;261: 10410.
  • 11
    Soini Y, Hurskainen T, Hoyhtya M, Oikarinen A, Autio-Harmainen H. 1994. 72 kd and 92 kd type IV collagenase, type IV collagen and laminin mRNAs in breast cancer: a study by in situ hybridization. J Histochem Cytochem 1994;42: 94551.
  • 12
    Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996;149: 27382.
  • 13
    El-Shabrawi Y, Neda Ardjomand, Radner H, Ardjomand N. MMP-9 is predominantly expressed in epitheliod and not spindle cell uveal melanoma. J Pathol 2001;194: 2016.
  • 14
    Kumaki F, Matsui K, Kawai T, Ozeki Y, Yu Z-X, Ferrans VJ, Travis WD. Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioalveolar component and atypical adenomatous hyperplasia. Am J Pathol 2001;159: 212535.
  • 15
    Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18: 113549.
  • 16
    Bond M, Fabunmi RP, Baker AH, Newby AC. Synergetic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998;435: 2934.
  • 17
    Lee PH, Hwang J-J, Murphy G, Margot MI. Functional significance of MMP-9 in tumor necrosis factor-induced proliferation and branching morphogenesis of mammary epithelial cells. Endocrinology 2000;141: 376473.
  • 18
    Himelstein BP, Lee EJ, Sato H, Seiki M, Muschel RJ. Transcriptional activation of matrix metalloproteinase-9 gene in H-ras and v-myc transformed rat embryo cell line. Oncogene 1997;14: 19958.
  • 19
    Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274: 214914.
  • 20
    Overall CM, Wrana JL, Sodek J. Independent regulation of collagenase, 72-kDa progelatinase, and metalloendopeptidase inhibitor expression in human fibroblasts by transforming growth-factor-β. J Biol Chem 1989;264: 18609.
  • 21
    Shimizu S, Nishikawa Y, Kuroda K, Takagi S, Kozaki K, Hyuga S, Saga S, Matsuyama M. Involvement of transforming growth factor β1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells. Cancer Res 1996;56: 336670.
  • 22
    Duivenvoorden WC, Hirte HW, Singh G. Transforming growth factor β1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis 1999;17: 2734.
  • 23
    Hagerdon HG, Bachmeier BE, Nerlich AG. Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-β in invasive carcinomas [review]. Intern J Oncol 2001;18: 66981.
  • 24
    Tremble P, Chiquet-Ehrismann R, Werb Z. The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol Cell Biol 1994;5: 43953.
  • 25
    Talhouk RS, Chin JR, Unemori EN, Werb Z, Bissel MJ. Proteinases of the mammary gland: developmental regulation in vivo and vectorial secretion in culture. Development 1991;112: 43949.
  • 26
    Jones PL, Boudreau N, Myers CA, Erickson HP, Bissell MJ. Tenascin-C inhibits extracellular matrix-dependent gene expression in mammary epithelial cells: localization of active regions using recombinant tenascin fragments. J Cell Sci 1995;108: 51927.
  • 27
    Saga Y, Yagi T, Ikawa Y, Sakakura T, Aizawa S. Mice develop normally without tenascin. Genes Devel 1992;6: 182131.
  • 28
    Saga Y, Tsukamoto T, Jing N, Kusakabe M, Sakakura T. Murine tenascin: cDNA cloning, structure and temporal expression of isoforms. Gene 1991;104: 177.
  • 29
    Mori M, Minori K, Shiraishi T, Fujie T, Baba K, Kusumoto H, Haraguchi M, Ueo H, Akiyoshi T. Analysis of MT1-MMP and MMP-2 expression in human gastric cancers. Int J Cancer 1997;74: 31621.
  • 30
    Van Trappen PO, Ryan A, Carroll M, Lecoeur C, Goff L, Gyselman VG, Young BD, Lowe DG, Pepper MS, Shepherd JH, Jacobs IJ. A model for co-expression pattern of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br J Cancer 2002;87: 53744.
  • 31
    Kalembeyi I, Yoshida T, Iriyama K, Sakakura T. Analysis of tenascin mRNA expression in the murine mammary gland from embryogenesis to carcinogenesis: an in situ hybridization study. Int J Dev Biol 1997;41: 56973.
  • 32
    Giambernardi TA, Grant GM, Taylor GP, Hay RJ, Maher VM, McCormick JJ, Klebe RJ. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 1998;16: 48396.
  • 33
    Kupferman ME, Fini ME, Muller WJ, Weber R, Cheng Y, Muschel RJ. Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression. Am J Pathol 2000;157: 177783.
  • 34
    Andersen K, Maelandsmo GM, Hovig E, Fodstad O, Loennechen T, Windberg JO. Interleukin-1 alpha and basic fibroblast growth factor induction of matrix metalloproteinases and their inhibitors in osteosarcoma cells is modulated by the metastasis associated protein CAPL. Anticancer Res 1998;18: 3299303.
  • 35
    Hazan RB, Philips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion and metastasis. J Cell Biol 2000;148: 77990.
  • 36
    Chiquet-Ehrismann R, Kalla P, Pearson CA. Participation of tenascin and transforming growth factor-beta in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts. Cancer Res 1989;49: 43225.
  • 37
    Mackie EJ, Chiquet-Ehrismann R, Pearson CA, Inaguma Y, Taya K, Kawarada Y, Sakakura T. Tenascin is a stromal marker of epithelial malignancy in the mammary gland. Proc Natl Acad Sci USA 1987;84: 46215.
  • 38
    Howeedy AA, Virtanen I, Laitinen L, Gould MS, Koukoulis GK, Gould VE. Differential distribution of tenascin in the normal, hyperplastic and neoplastic breast. Lab Invest 1990;63: 798806.
  • 39
    Gorsch SM, Memoli VA, Stukel TA, Gold Li, Arrick BA. Immunohistochemical staining for transforming growth factor beta1 associates with disease progression in human breast cancer. Cancer Res 1992;52: 694952.
  • 40
    Lebeau A, Nerlich AG, Sauer U, Lichtinghagen R, Lohrs U. Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas. Anticancer Res 1999;19: 425764.
  • 41
    Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29: 11729.
  • 42
    Imai K, Kusakabe M, Sakakura T, Nakanishi I, Okada Y. Susceptibility of tenascin to degradation by matrix metalloproteinases and serine proteinases. FEBS Lett 1994;352: 2168.
  • 43
    Siri A, Knauper V, Veirana, N, Caocci F, Murphy G, Zardi L. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem 1995;270: 86504.
  • 44
    Jones PL, Crack J, Rabinovitch M. 1997. Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alfaVbeta3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol 1997;139: 27993.
  • 45
    Jian B, Jones PL, Li Q, Mohler III ER, Schoen FJ, Levy RJ. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 2001;159: 3217.
  • 46
    Remacle AG, Noel A, Duggan C, McDermott E, O'Higgins N, Foidart JM, Duffy MJ. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 1998;77: 92631.
  • 47
    Brummer O, Athar S, Riethdorf L, Loning T, Herbst H. Matrix-metalloproteinases 1, 2 and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch 1999;435: 56673.
  • 48
    Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999;189: 1618.
  • 49
    van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415: 5305.
  • 50
    Sehgal I, Thompson TC. 1999. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-β1 in human prostate cancer cell lines. Mol Biol Cell 1999;10: 40716.
  • 51
    Festuccia C, Angelucci A, Gravina GL, Villanova I, Teti A. Osteoblast-derived TGF-β1 modulates matrix degrading protease expression and activity in prostate cancer cells. Int J Cancer 2000;85: 40715.
  • 52
    Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin upregulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 1997;70: 7226.
  • 53
    Mira E, Manes S, Lacalle RA, Marquez G, Martinez-A C. Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology 1999;140: 165764.
  • 54
    Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, Cippitelli M. bcl-2 over-expression enhances NF-kB activity and induces mmp-9 transcription in human MCF7ADR breast cancer cells. Int J Cancer 2000;86: 18896.
  • 55
    Schedin P, Strange R, Mitrenga T, Wolfe, Kaeck M. Fibronectin fragments induce MMP activity in mouse mammary epithelial cells: evidence for a role in mammary tissue remodeling. J Cell Sci 2000;113: 795806.
  • 56
    Swindle CS, Tran KT, Johnson TD, Banerjee P, Mayes AN, Griffith L, Wells A. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol 2001;154: 454968.